Tweet
harmaceuticals (Basel)
. 2022 Jan 8;15(1):78.
doi: 10.3390/ph15010078.
A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis
Jaime Monserrat Villatoro 1 , Gina Mejía-Abril 2 , Lucía Díaz García 1 , Pablo Zubiaur 2 , María Jiménez González 3 , Guillermo Fernandez Jimenez 4 , Inés Cancio 4 , José Ramón Arribas 5 , Carmen Suarez Fernández 6 , Jesús Mingorance 7 , Julio García Rodríguez 7 , José Ramón Villagrasa Ferrer 8 , Antonio J Carcas 1 , Jesús Frías 1 , Francisco Abad-Santos 2 , Alberto M Borobia 1 , Elena Ramírez 1 , On Behalf Of The Covid Hulp Working Group And Other Collaborators From Hospital Universitario de la Princesa
Affiliations
- PMID: 35056135
- DOI: 10.3390/ph15010078
Abstract
Data from several cohorts of coronavirus disease 2019 (COVID-19) suggest that the most common comorbidities for severe COVID-19 disease are the elderly, high blood pressure, and diabetes; however, it is not currently known whether the previous use of certain drugs help or hinder recovery. This study aims to explore the association of previous hospitalisation use of medication on the mortality of COVID-19 disease. A retrospective case-control from two hospitals in Madrid, Spain, included all patients aged 18 years or above hospitalised with a diagnosis of COVID-19. A Propensity Score matching (PSM) analysis was performed. Confounding variables were considered to be age, sex, and the number of comorbidities. Finally, 3712 patients were included. Of these, 687 (18.5%) patients died (cases). The 22,446 medicine trademarks used previous to admission were classified according to the ATC, obtaining 689 final drugs; all of them were included in PSM analysis. Eleven drugs displayed a reduction in mortality: azithromycin, bemiparine, budesonide-formoterol fumarate, cefuroxime, colchicine, enoxaparin, ipratropium bromide, loratadine, mepyramine theophylline acetate, oral rehydration salts, and salbutamol sulphate. Eight final drugs displayed an increase in mortality: acetylsalicylic acid, digoxin, folic acid, mirtazapine, linagliptin, enalapril, atorvastatin, and allopurinol. Medication associated with survival (anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with mortality show an interaction with the underlying conditions.
Keywords: coronavirus disease 2019 (COVID-19); hospitalisation; mortality; previous medication; propensity score matching analysis; risk factor; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).